Matches in Nanopublications for { ?s ?p "[Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be considered for OSCC in a subset of patients with these mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP316617.RAVZrG2cosDZtbHLgizbuLhg9F3N0pdob7pUJaM2sSgzg130_assertion description "[Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be considered for OSCC in a subset of patients with these mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP316617.RAVZrG2cosDZtbHLgizbuLhg9F3N0pdob7pUJaM2sSgzg130_provenance.
- NP667888.RA9EVfcAMLPGLwGZHr8vYIBK4tPYhlzX4pNyUehsP1Dzc130_assertion description "[Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be considered for OSCC in a subset of patients with these mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP667888.RA9EVfcAMLPGLwGZHr8vYIBK4tPYhlzX4pNyUehsP1Dzc130_provenance.
- assertion description "[Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be considered for OSCC in a subset of patients with these mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP836756.RAAkSXg4u148mgf0VI1eRkm02d70JQNcaSAp4rFnKFtvI130_assertion description "[Our study supports that mutations in the BRAF, KRAS, and PIK3CA genes make at least a minor contribution to OSCC tumorigenesis, and pathway-specific therapies targeting these 2 pathways should be considered for OSCC in a subset of patients with these mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP836756.RAAkSXg4u148mgf0VI1eRkm02d70JQNcaSAp4rFnKFtvI130_provenance.